Last Updated:2022/12/24
More recently, other biological drugs, such as ustekinumab, ixekizumab, tofacitinib, secukinumab and briakinumab, have targeted immunological mediators of the disease.
音声機能が動作しない場合はこちらをご確認ください
Edit Histories(0)